

Subject:	Vaccines For Children (VFC)		
Policy Number:	PO-RE-081v2		
Effective Date:	01/01/2025	Last Approval Date:	1/15/2026

I. Policy Description

This policy outlines the reimbursement procedures for Vaccines for Children (VFC) at Healthfirst, ensuring compliance with New York State (NYS) Medicaid guidelines. The VFC program is designed to provide access to vaccines for eligible children under the age of nineteen (19) years old, thereby promoting public health and preventing disease outbreaks.

The information below applies to the following lines of business:

- Child Health Plus
- Medicaid Managed Care

Policy Scope

This policy is applicable to children under the age of 19 who meet the eligibility criteria. Vaccines covered by the VFC program are those recommended by the Advisory Committee on Immunization Practices (ACIP), a federal advisory group that develops immunization recommendations for the United States. These recommendations are then forwarded to and adopted by the Center for Disease Control and Prevention (CDC).

Providers who wish to participate in the VFC program must enroll through the Citywide Immunization Registry (CIR). VFC providers must agree to follow all VFC requirements and complete the necessary training as required by the Centers for Disease Control and Prevention (CDC). More information how to enroll in the VFC program can be found here: [Vaccines for Children Provider Requirements - NYC Health](#)

Reimbursement Guidelines

Modifier Usage

- The SL modifier must be appended to claims submitted for federal and state-funded vaccines. This indicates that the vaccine was provided through the VFC program and is essential for correct reimbursement.

Documentation

- Comprehensive documentation must be maintained to support claims, including
 - Patient eligibility verification.
 - Vaccine administration records.
 - Any other relevant medical records.

Reimbursement

- Healthfirst will reimburse for the administration costs of the vaccines that are funded by Federal and State resources.
- Reimbursement for administration is only given to CPT 90460, 90471-90474 for vaccines billed under the VFC program.
- Healthfirst will not reimburse for vaccines supplied by Vaccine for Children (VFC) program or other funded programs.

Adjudication and Appeal Process

1. Claims submitted by providers that do not adhere to this policy will be denied or rejected. It is the responsibility of the provider to ensure claims are coded accurately.
2. This policy applies only to the line(s) of business (LOB) identified at the beginning of the policy and does not apply to other LOBs. For policies applicable to other lines of business, please visit www.hfproviders.org.
3. This policy is a provider resource for understanding Healthfirst's reimbursement guidelines. It does not guarantee coverage or payment. Final reimbursement decisions depend on benefit coverage, state/federal mandates, medical necessity, and provider contract.
4. Claims submissions will be subject to timely filing requirements, as set forth in the provider contract with Healthfirst and in the Healthfirst Provider Manual. *Refer to: Healthfirst Provider Manual Subsection 17.6, "Claims Inquiries, Corrected Claims, Claim Reconsideration, and Appeal Process" in this section.*

Note: Healthfirst has a separate policy regarding vaccinations that do not fall under the VFC program. This policy can be found under the Related Polices section of this document.

II. Applicable Codes

Code	Description	Comment
90291	Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use	
90371	Hepatitis B immune globulin (HBIG), human, for	

	intramuscular use	
90375	Rabies immune globulin (Rig), human, for intramuscular and/or subcutaneous use	
90376	Rabies immune globulin, heat-treated (Rig-HT), human, for intramuscular and/or subcutaneous use	
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each	
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	
90382	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use	
90389	Tetanus immune globulin (Tlg), human, for intramuscular use	
90393	Vaccinia immune globulin, human, for intramuscular use	
90396	Varicella-zoster immune globulin, human, for intramuscular use	
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered	Administration
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	Administration
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	Administration
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)	Administration
90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for	Administration

	primary procedure)	
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose	Administration
90584	Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use	
90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use	
90587	Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use	
90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	
90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use	
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	
90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use	
90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	
90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use	
90632	Hepatitis A vaccine (HepA), adult dosage, for intramuscular use	

90633	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	
90634	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use	
90636	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use	
90644	Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use	
90647	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	
90648	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	
90649	Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use	
90650	Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use	
90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	
90653	Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use	
90655	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use	
90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use	
90657	Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use	
90658	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use	
90660	Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use	

90661	Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	
90662	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	
90670	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	
90671	Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use	
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	
90673	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	
90674	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	
90675	Rabies vaccine, for intramuscular use	
90676	Rabies vaccine, for intradermal use	
90677	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	
90680	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	
90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	

90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	
90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use	
90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	
90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use	
90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	
90689	Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use	
90690	Typhoid vaccine, live, oral	
90691	Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use	
90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use	
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	
90697	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use	
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use	
90702	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for	

	intramuscular use	
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	
90713	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	
90714	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	
90716	Varicella virus vaccine (VAR), live, for subcutaneous use	
90717	Yellow fever vaccine, live, for subcutaneous use	
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	
90732	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	
90733	Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use	
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use	
90736	Zoster (shingles) vaccine (HZV), live, for subcutaneous injection	
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use	
90739	Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use	
90740	Hepatitis B vaccine (HepB), dialysis or immunosuppressed	

	patient dosage, 3 dose schedule, for intramuscular use	
90743	Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use	
90744	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	
90746	Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	
90747	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use	
90748	Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use	
90749	Unlisted vaccine/toxoid	
90750	Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use	
90756	Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use	
90759	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use	
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use	
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	

91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	
96380	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional	Administration
96381	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection	Administration

III. Definitions

Term	Meaning

IV. Related Policies

Policy Number	Policy Description
PO-RE-109	Vaccine Administration

Current Procedural Terminology © American Medical Association. All rights reserved.

Procedure codes appearing in Reimbursement Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Reference Materials

Current CDC Vaccine Price List VFC Program CDC
--

IIS Code Sets CPT Vaccines CDC
Medicaid Covered Vaccines
Medicaid Pharmacy Program
Vaccines for Children Provider Requirements - NYC Health
How to Enroll - Vaccines for Children (VFC) Program (ny.gov)
Citywide Immunization Registry (CIR) - NYC Health

VI. Revision History

Revision Date	Summary of Changes
01/15/2026	14 CPT codes were added to the Applicable Codes section. CPT Codes: 90291, 90375, 90376, 90378, 90389, 90393, 90396, 90589, 90611, 90622, 90623, 90679, 90683, 90759

Disclaimer

Healthfirst’s claim edits follow national industry standards aligned with CMS standards that include, but are not limited to, the National Correct Coding Initiative (NCCI), the National and Local Coverage Determination (NCD/LCD) policies, appropriate modifier usage, global surgery and multiple procedure reduction rules, medically unlikely edits, duplicates, etc. In addition, Healthfirst’s coding edits incorporate industry-accepted AMA and CMS CPT, HCPCS and ICD-10 coding principles, National Uniform Billing Editor’s revenue coding guidelines, CPT Assistant guidelines, New York State-specific coding, billing, and payment policies, as well as national physician specialty academy guidelines (coding and clinical). Failure to follow proper coding, billing, and/or reimbursement policy guidelines could result in the denial and/or recoupment of the claim payment.

This policy is intended to serve as a resource for providers to use in understanding reimbursement guidelines for professional and institutional claims. This information is accurate and current as of the date of publication. It provides information from industry sources about proper coding practice. However, this document does not represent or guarantee that Healthfirst will cover and/or pay for services outlined. Reimbursement decisions are based on the terms of the applicable evidence of coverage, state and federal requirements or mandates, and the provider’s participation agreement. This includes the determination of any amounts that Healthfirst or the member owes the provider.